Media
THE DAILY MAIL: An off-the-shelf cancer vaccine could help prevent relapse in patients with two of the deadliest and fastest-rising cancers in the world. The shot is designed for patients whose cancers are caused by the KRAS mutation, which accounts for up to nine in 10 cases of the disease.
THE PHARMA LETTER: Along with the big pharma players showing off the potential of their cancer drugs at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), biotech companies have been making their presence felt, too.
BIOTECH TV: Anirban Maitra and Shubham Pant from MD Anderson tell us what targets and approaches look promising in pancreatic cancer.
GLOBES: Elicio Therapeutics reports positive interim results from a Phase 1 trial at risk of relapse after surgery or chemotherapy.
CLINICAL TRIALS ARENA: ELI-002 2P was well-tolerated with no dose limiting toxicity or cytokine release syndrome across five cohorts.
O’Reilly EM, Wainberg ZA, Weekes CD, et al.
Presented at the American Society of Clinical Oncology Annual Meeting
June 2-6, 2023
Chicago, IL
PRECISION MEDICINE ONLINE: Elicio Therapeutics on Thursday said it closed a previously announced reverse merger with Angion
MARKETWATCH: Shares of Elicio Therapeutics were trading higher on the Nasdaq Friday, following the combination of the company with Angion Biomedica.
LABIOTECH: Elicio Therapeutics specializes in immunotherapeutic research in the field of cancer and infectious diseases. And its amphiphile technology (AMP) platform is the foundation for the various vaccine candidates in its pipeline, against cancer and other diseases.
PHARMA’S ALMANAC: I’ve seen two areas within oncology in particular that have grown significantly with revolutionary potential in the coming year: therapeutics targeting KRAS mutations and the re-emergence of cancer vaccines. Christopher Haqq, MD, PhD